Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Section 6 of 6

References

184 sources

  1. Alkhouri et al. (2024) (opens in a new tab)
  2. American Diabetes Association Professional Practice Committee (2026) (opens in a new tab)
  3. Apovian et al. (2015) (opens in a new tab)
  4. Ard et al. (2026) (opens in a new tab)
  5. Aronne et al. (2024) (opens in a new tab)
  6. Aronne et al. (2025) (opens in a new tab)
  7. Aronne et al. (2026) (opens in a new tab)
  8. Atlas et al. (2023) (opens in a new tab)
  9. Bays et al. (2025) (opens in a new tab)
  10. Bays et al. (2026a) (opens in a new tab)
  11. Bays et al. (2026b) (opens in a new tab)
  12. Betensky et al. (2025) (opens in a new tab)
  13. Bhaskaran et al. (2018) (opens in a new tab)
  14. Busebee et al. (2023) (opens in a new tab)
  15. Busetto et al. (2024) (opens in a new tab)
  16. Cawley et al. (2021) (opens in a new tab)
  17. CBO (2024) (opens in a new tab)
  18. CDC Adult BMI Categories (2024) (opens in a new tab)
  19. CDC Adult Obesity Prevalence Maps (2026) (opens in a new tab)
  20. CDC Risk Factors for Obesity (2025) (opens in a new tab)
  21. Celletti et al. (2026) (opens in a new tab)
  22. Chao et al. (2020) (opens in a new tab)
  23. Chetty et al. (2025) (opens in a new tab)
  24. Chung et al. (2026) (opens in a new tab)
  25. ClinicalTrials.gov NCT05203237 (opens in a new tab)
  26. ClinicalTrials.gov NCT06068946 (opens in a new tab)
  27. ClinicalTrials.gov NCT06828055 (opens in a new tab)
  28. ClinicalTrials.gov NCT07104383 (opens in a new tab)
  29. ClinicalTrials.gov NCT07104500 (opens in a new tab)
  30. ClinicalTrials.gov NCT07838740 (opens in a new tab)
  31. ClinicalTrials.gov NCT07868835 (opens in a new tab)
  32. ClinicalTrials.gov NCT07868939 (opens in a new tab)
  33. CMS BALANCE Model (2026) (opens in a new tab)
  34. CMS Medicare GLP-1 Bridge (2026) (opens in a new tab)
  35. CMS Quality Payment Program measure 128 (2026) (opens in a new tab)
  36. Davies et al. (2021) (opens in a new tab)
  37. Do et al. (2024) (opens in a new tab)
  38. Eisenberg et al. (2022) (opens in a new tab)
  39. Eli Lilly Foundayo approval announcement (2026) (opens in a new tab)
  40. Eli Lilly Foundayo coverage and savings (2026) (opens in a new tab)
  41. Eli Lilly Foundayo prescribing information (2026) (opens in a new tab)
  42. Eli Lilly Zepbound coverage and savings (2026) (opens in a new tab)
  43. Eli Lilly Zepbound KwikPen announcement (2026) (opens in a new tab)
  44. Eli Lilly Zepbound prescribing information (2026) (opens in a new tab)
  45. Eli Lilly Zepbound pricing information (2026) (opens in a new tab)
  46. Emmerich et al. (2024) (opens in a new tab)
  47. FDA weight reduction draft guidance (2025) (opens in a new tab)
  48. FDA weight reduction draft guidance notice (2025) (opens in a new tab)
  49. Flølo et al. (2026) (opens in a new tab)
  50. Fryar et al. (2026) (opens in a new tab)
  51. Gadde et al. (2011) (opens in a new tab)
  52. Garvey et al. (2022) (opens in a new tab)
  53. Garvey et al. (2023) (opens in a new tab)
  54. Garvey et al. (2025) (opens in a new tab)
  55. GBD 2015 Obesity Collaborators (2017) (opens in a new tab)
  56. GBD 2021 Adult BMI Collaborators (2025) (opens in a new tab)
  57. GBD 2021 US Obesity Forecasting Collaborators (2024) (opens in a new tab)
  58. Gilbert et al. (2025) (opens in a new tab)
  59. Gleason et al. (2024) (opens in a new tab)
  60. Global BMI Mortality Collaboration (2016) (opens in a new tab)
  61. Greenway et al. (2010) (opens in a new tab)
  62. Grunvald et al. (2022) (opens in a new tab)
  63. Guh et al. (2009) (opens in a new tab)
  64. Hedges et al. (2026) (opens in a new tab)
  65. Hennessy et al. (2026) (opens in a new tab)
  66. Horn et al. (2026a) (opens in a new tab)
  67. Horn et al. (2026b) (opens in a new tab)
  68. Hwang et al. (2025) (opens in a new tab)
  69. ICER (2025) (opens in a new tab)
  70. Ippolito and Levy (2024) (opens in a new tab)
  71. ISRCTN ISRCTN47896018 (opens in a new tab)
  72. Jastreboff et al. (2022) (opens in a new tab)
  73. Jastreboff et al. (2025) (opens in a new tab)
  74. Jastreboff et al. (2026) (opens in a new tab)
  75. Jensen et al. (2014) (opens in a new tab)
  76. Johansson et al. (2026) (opens in a new tab)
  77. KFF (2025) (opens in a new tab)
  78. Kim et al. (2022) (opens in a new tab)
  79. Kivimäki et al. (2022) (opens in a new tab)
  80. Kolotkin and Andersen (2017b) (opens in a new tab)
  81. Kolotkin et al. (2017a) (opens in a new tab)
  82. Kosiborod et al. (2023) (opens in a new tab)
  83. Lauby-Secretan et al. (2016) (opens in a new tab)
  84. Lian et al. (2023) (opens in a new tab)
  85. Lincoff et al. (2023) (opens in a new tab)
  86. Lingvay et al. (2025) (opens in a new tab)
  87. Luppino et al. (2010) (opens in a new tab)
  88. MacEwan et al. (2024) (opens in a new tab)
  89. Malhotra et al. (2024) (opens in a new tab)
  90. Marshall et al. (2026) (opens in a new tab)
  91. Mercer (2025) (opens in a new tab)
  92. Modesto et al. (2025a) (opens in a new tab)
  93. Modesto et al. (2025b) (opens in a new tab)
  94. Modesto et al. (2025c) (opens in a new tab)
  95. Montero et al. (2024) (opens in a new tab)
  96. Nadolsky et al. (2025) (opens in a new tab)
  97. NCD Risk Factor Collaboration (2024) (opens in a new tab)
  98. Neutel et al. (2024) (opens in a new tab)
  99. Nielsen et al. (2023) (opens in a new tab)
  100. Novo Nordisk list price reduction announcement (2026) (opens in a new tab)
  101. Novo Nordisk Wegovy pill approval announcement (2025) (opens in a new tab)
  102. Novo Nordisk Wegovy prescribing information (2026) (opens in a new tab)
  103. Novo Nordisk Wegovy pricing information (2026) (opens in a new tab)
  104. ODPHP Healthy People 2030 NWS-03 (opens in a new tab)
  105. Okunogbe et al. (2022) (opens in a new tab)
  106. Pennings et al. (2025) (opens in a new tab)
  107. Peppard et al. (2013) (opens in a new tab)
  108. Pi-Sunyer et al. (2015) (opens in a new tab)
  109. Powell-Wiley et al. (2021) (opens in a new tab)
  110. Rodriguez et al. (2025) (opens in a new tab)
  111. Ross et al. (2020) (opens in a new tab)
  112. Rozjabek et al. (2020) (opens in a new tab)
  113. Rubino et al. (2020) (opens in a new tab)
  114. Rubino et al. (2024) (opens in a new tab)
  115. Rubino et al. (2025) (opens in a new tab)
  116. Ryan et al. (2024) (opens in a new tab)
  117. Sanyal et al. (2025) (opens in a new tab)
  118. Schwartz et al. (2017) (opens in a new tab)
  119. Shinde et al. (2024) (opens in a new tab)
  120. Syn et al. (2021) (opens in a new tab)
  121. Tchang et al. (2025) (opens in a new tab)
  122. Thorpe and Joski (2024) (opens in a new tab)
  123. Torgerson et al. (2004) (opens in a new tab)
  124. US Preventive Services Task Force (2018) (opens in a new tab)
  125. Vasan et al. (2005) (opens in a new tab)
  126. Viking Therapeutics chief commercial officer appointment release (2026) (opens in a new tab)
  127. Viking Therapeutics CordenPharma agreement release (2025) (opens in a new tab)
  128. Viking Therapeutics corporate presentation (2026) (opens in a new tab)
  129. Viking Therapeutics ECO 2026 release (2026) (opens in a new tab)
  130. Viking Therapeutics first quarter 2026 earnings call transcript (2026) (opens in a new tab)
  131. Viking Therapeutics Form 10-K (2026) (opens in a new tab)
  132. Viking Therapeutics Form 10-Q third quarter (2026) (opens in a new tab)
  133. Viking Therapeutics fourth quarter 2024 results release (2025) (opens in a new tab)
  134. Viking Therapeutics fourth quarter 2025 earnings call transcript (2026) (opens in a new tab)
  135. Viking Therapeutics fourth quarter 2025 results release (2026) (opens in a new tab)
  136. Viking Therapeutics J.P. Morgan conference transcript (2026) (opens in a new tab)
  137. Viking Therapeutics Jefferies conference transcript (2026) (opens in a new tab)
  138. Viking Therapeutics Jefferies London conference transcript (2025) (opens in a new tab)
  139. Viking Therapeutics maintenance study enrollment release (2026) (opens in a new tab)
  140. Viking Therapeutics maintenance study initiation release (2025) (opens in a new tab)
  141. Viking Therapeutics maintenance study presentation (2026) (opens in a new tab)
  142. Viking Therapeutics maintenance study topline call transcript (2026) (opens in a new tab)
  143. Viking Therapeutics maintenance study topline release (2026) (opens in a new tab)
  144. Viking Therapeutics Morgan Stanley conference transcript (2026) (opens in a new tab)
  145. Viking Therapeutics ObesityWeek 2021 preclinical release (2021) (opens in a new tab)
  146. Viking Therapeutics ObesityWeek 2023 release (2023) (opens in a new tab)
  147. Viking Therapeutics ObesityWeek 2024 release (2024) (opens in a new tab)
  148. Viking Therapeutics ObesityWeek 2025 release (2025) (opens in a new tab)
  149. Viking Therapeutics ObesityWeek 2026 release (2026) (opens in a new tab)
  150. Viking Therapeutics oral maintenance study initiation release (2026) (opens in a new tab)
  151. Viking Therapeutics oral phase 1 initiation release (2023) (opens in a new tab)
  152. Viking Therapeutics oral phase 1 results release (2024) (opens in a new tab)
  153. Viking Therapeutics phase 1 initiation release (2022) (opens in a new tab)
  154. Viking Therapeutics phase 1 results release (2023) (opens in a new tab)
  155. Viking Therapeutics second quarter 2026 earnings call transcript (2026) (opens in a new tab)
  156. Viking Therapeutics SUNRISE initiation release (2026) (opens in a new tab)
  157. Viking Therapeutics third quarter 2024 results release (2024) (opens in a new tab)
  158. Viking Therapeutics third quarter 2025 earnings call transcript (2025) (opens in a new tab)
  159. Viking Therapeutics third quarter 2026 earnings call transcript (2026) (opens in a new tab)
  160. Viking Therapeutics third quarter 2026 results release (2026) (opens in a new tab)
  161. Viking Therapeutics VANQUISH initiation release (2025) (opens in a new tab)
  162. Viking Therapeutics VANQUISH-1 enrollment release (2025) (opens in a new tab)
  163. Viking Therapeutics VANQUISH-2 enrollment release (2026) (opens in a new tab)
  164. Viking Therapeutics VENTURE enrollment release (2023) (opens in a new tab)
  165. Viking Therapeutics VENTURE initiation release (2023) (opens in a new tab)
  166. Viking Therapeutics VENTURE topline release (2024) (opens in a new tab)
  167. Viking Therapeutics VENTURE-Oral enrollment release (2025) (opens in a new tab)
  168. Viking Therapeutics VENTURE-Oral initiation release (2025) (opens in a new tab)
  169. Viking Therapeutics VENTURE-Oral topline call transcript (2025) (opens in a new tab)
  170. Viking Therapeutics VENTURE-Oral topline release (2025) (opens in a new tab)
  171. Viking Therapeutics VK2735 pipeline page (opens in a new tab)
  172. Ward et al. (2019) (opens in a new tab)
  173. Ward et al. (2021) (opens in a new tab)
  174. West et al. (2026) (opens in a new tab)
  175. Wharton et al. (2025a) (opens in a new tab)
  176. Wharton et al. (2025b) (opens in a new tab)
  177. Wharton et al. (2025c) (opens in a new tab)
  178. WHO (2026) (opens in a new tab)
  179. Wilding et al. (2021) (opens in a new tab)
  180. Wilding et al. (2022) (opens in a new tab)
  181. Wyatt et al. (2026) (opens in a new tab)
  182. Xu et al. (2018) (opens in a new tab)
  183. Zheng and Chen (2015) (opens in a new tab)
  184. Zvenyach and Pickering (2023) (opens in a new tab)